Sophiris Bio Inc (NASDAQ:SPHS) has earned an average recommendation of “Buy” from the six brokerages that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $6.60.
SPHS has been the topic of several recent analyst reports. Maxim Group set a $6.00 price objective on shares of Sophiris Bio and gave the company a “buy” rating in a research report on Monday, August 14th. HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of Sophiris Bio in a research report on Friday, September 15th. Finally, ValuEngine downgraded shares of Sophiris Bio from a “hold” rating to a “sell” rating in a research report on Tuesday, June 13th.
Sophiris Bio (SPHS) traded up 2.31% on Wednesday, reaching $2.40. 448,776 shares of the company traded hands. The stock’s 50 day moving average price is $2.15 and its 200 day moving average price is $2.29. Sophiris Bio has a one year low of $1.80 and a one year high of $3.30. The company’s market capitalization is $72.27 million.
COPYRIGHT VIOLATION WARNING: This piece of content was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://stocknewstimes.com/2017/10/09/sophiris-bio-inc-sphs-given-average-recommendation-of-buy-by-analysts.html.
An institutional investor recently bought a new position in Sophiris Bio stock. Mesirow Financial Investment Management Inc. bought a new position in shares of Sophiris Bio Inc (NASDAQ:SPHS) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 54,510 shares of the biopharmaceutical company’s stock, valued at approximately $120,000. Mesirow Financial Investment Management Inc. owned 0.18% of Sophiris Bio at the end of the most recent quarter. Hedge funds and other institutional investors own 6.01% of the company’s stock.
Sophiris Bio Company Profile
Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).
Receive News & Ratings for Sophiris Bio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio Inc and related companies with MarketBeat.com's FREE daily email newsletter.